<DOC>
	<DOC>NCT00989469</DOC>
	<brief_summary>A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.</brief_summary>
	<brief_title>Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 Written informed consent Histologically proven adenocarcinoma of the colon or rectum asymptomatic primary tumour or surgically removed mCRC patients with previously unresectable metastatic disease Patient with at least one tumoral lesion: measurable in a unidimensional way with a spiral scanner according to RECIST, no previous irradiation in this area Disease progression after irinotecanbased chemotherapy Disease progression after one or more previous lines of chemotherapy received in metastatic situation WHO &lt;= 2 Patient having a mutated KRAS on 12 or 13 codons on the primary tumour or a metastasis Adequate liver function : Bilirubin ≤ 1,5 x UNL, ASAT ou ALAT ≤ 2,5 x UNL (or &lt; 5 x UNL for subjects having a hepatic insufficiency in connection with hepatic metastases) Polynuclear neutrophils ≥ 1 500/mm3 Haemoglobin &gt; 10g/dl Platelets ≥ 100 000/mm3 Amylase and lipase &lt; 1,5 x UNL Serum Creatinin &lt; 1,5 x UNL Adapted contraceptive measures during treatment and continued at least three months after end of the treatment Life expectancy &gt; 3 months Affiliated to or benefiting from health insurance Gilbert's disease Brain metastases or carcinomatous symptomatic meningitis Exclusive bone metastasis Previous cancers not considered as cured in the 5 years before inclusion (except for basocellular skin carcinoma) Surgery (except diagnostic biopsy) or radiotherapy within 4 weeks before inclusion Disorders of the cardiac rhythm requiring an antiasynchronous treatment (except beta blockers or digoxine within the framework of a chronic auricular fibrillation), unstable coronaropathy or myocardial infarction &lt; 6 months, congestive cardiac failure &gt; Rank II NYHA (Grade 2), uncontrolled arterial hypertension Previous epilepsy crises requiring long term antiepileptic treatment Previous organ transplant requiring immunosuppressor treatment Severe bacterial or fungus infection (&gt; Grade 2 NCI CTC version 3) Known HIV Infection Long term treatment by known inductors of the CYP 3A4 like Rifampicin, Millepertuis (hypericum perforatum), Phenytoin, Carbamazepin, Phenobarbital, Dexamethasone et Ketonazole Known allergy to one of the therapeutic agents Reasons (psychological, family, social or geographical) that could compromise the participation of the patient in the study Intestinal malabsorption or gastrointestinal surgery being able to affect Sorafenib absorption. Occlusive or subocclusive syndrome. Dysphagic patient or patient not being able to take treatment by orally inflammatory Chronic digestive disease involving chronic diarrhoea (NCI N+Bethesda &gt;= 1.2g) Participation in another clinical trial within 30 days before the start of this study Other concomitant experimental drugs or other concomitant anticancer agents (except Irinotecan and Sorafenib) Medical or psychological state that in the opinion of the investigator will not allow the patient to terminate the study or to understand and sign the informed consent form Pregnancy and breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>